Shanghai Rightongene Biotechnology Stock EBITDA
| 688217 Stock | 20.84 0.26 1.23% |
Shanghai Rightongene Biotechnology fundamentals help investors to digest information that contributes to Shanghai Rightongene's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Rightongene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Rightongene stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 123.9 M | 86.3 M |
Shanghai | EBITDA |
Shanghai Rightongene Biotechnology Company EBITDA Analysis
Shanghai Rightongene's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Shanghai Rightongene EBITDA | 25.94 M |
Most of Shanghai Rightongene's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Rightongene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Shanghai Ebitda
Ebitda |
|
According to the company disclosure, Shanghai Rightongene Biotechnology reported earnings before interest,tax, depreciation and amortization of 25.94 M. This is 97.04% lower than that of the Biotechnology sector and 74.1% lower than that of the Health Care industry. The ebitda for all China stocks is 99.33% higher than that of the company.
Shanghai EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Rightongene's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Rightongene could also be used in its relative valuation, which is a method of valuing Shanghai Rightongene by comparing valuation metrics of similar companies.Shanghai Rightongene is currently under evaluation in ebitda category among its peers.
Shanghai Fundamentals
| Return On Equity | -0.0148 | ||||
| Return On Asset | -0.0097 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 964.1 M | ||||
| Shares Outstanding | 55.86 M | ||||
| Shares Owned By Insiders | 40.64 % | ||||
| Shares Owned By Institutions | 15.60 % | ||||
| Price To Book | 1.25 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 258.21 M | ||||
| Gross Profit | 257.7 M | ||||
| EBITDA | 25.94 M | ||||
| Net Income | 7.93 M | ||||
| Total Debt | 5.82 M | ||||
| Book Value Per Share | 14.70 X | ||||
| Cash Flow From Operations | 45.1 M | ||||
| Earnings Per Share | (0.10) X | ||||
| Number Of Employees | 501 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | 154.03 M | ||||
| Working Capital | 467.29 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 1.04 B |
About Shanghai Rightongene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Rightongene Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Rightongene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Rightongene Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Rightongene financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Rightongene security.